Registro:

Referencias:

• Agarwal, M.K., Mirshahi, M., General overview of mineralocorticoid action (2000) Pharmacol. Ther., 84, pp. 273-326
• Alnemri, E.S., Maksymowych, A.B., Robertson, N.M., Litwack, G., Overexpression and characterization of the human mineralocorticoid receptor (1991) J. Biol. Chem., 266, pp. 18072-18081
• Bastl, C.P., Hayslett, J.P., The cellular action of aldosterone in target epithelia (1992) Kidney Int., 42, pp. 250-264
• Brachet-Cota, A.L., Burton, G., An improved preparation of 11,19-oxidopregn-4-ene-3,20-dione and 6,19-oxidopregn-4-ene-3,11,20-trione (1990) Z. Naturforsch. T.b, 45, pp. 711-715
• Burton, G., Galigniana, M.D., DeLavallaz, S., Brachet-Cota, A.L., Sproviero, E.M., Ghini, A.A., Lantos, C.P., Sodium-retaining activity of some natural and synthetic 21-deoxysteroids (1995) Mol. Pharmacol., 47, pp. 535-543
• Chen, H., Lin, R.J., Xie, W., Wilpitz, D., Evans, R.M., Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase (1999) Cell, 98, pp. 675-686
• Dluhy, R.G., Glucocorticoid-remediable aldosteronism (2001) Endocrinologist, 11, pp. 263-268
• Fagart, J., Wurtz, J.M., Souque, A., Hellal-Levy, C., Moras, D., Rafestin-Oblin, M.E., Antagonism in the human mineralocorticoid receptor (1998) EMBO J., 17, pp. 3317-3325
• Farman, N., Rafestin-Oblin, M.E., Multiple aspects of mineralocorticoid selectivity (2001) Am. J. Physiol. Renal Physiol., 280, pp. F181-F192
• Funder, J.W., Aldosterone action: Fact, failure and the future (1998) Clin. Exp. Pharmacol. Physiol., 25, pp. S47-S50
• Funder, J.W., Aldosterone and mineralocorticoid receptors: Orphan questions (2000) Kidney Int., 57, pp. 1358-1363
• Funder, J.W., Pearce, P., Smith, R., Smith, A.I., Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated (1988) Science, 242, pp. 583-585
• Galigniana, M.D., Native rat kidney mineralocorticoid receptor is a phosphoprotein whose transformation to a DNA-binding form is induced by phosphatases (1998) Biochem. J., 333, pp. 555-563
• Galigniana, M.D., Functional regulation of corticosteroid receptors by phosphorylation and redox potential (2000) Curr. Top. Steroid Res., 3, pp. 1-22
• Galigniana, M.D., Piwien-Pilipuk, G., Comparative inhibition by hard and soft metal ions on steroid-binding capacity of renal mineralocorticoid receptor cross-linked to the 90-kDa heat-shock protein heterocomplex (1999) Biochem. J., 341, pp. 585-592
• Galigniana, M.D., Vicent, G.P., Lantos, C.P., Burton, G., Ligand properties of 11,19-oxidoprogesterone: A preliminary report (1993) An. Asoc. Quím. Argent., 81, pp. 333-340
• Galigniana, M.D., Vicent, G.P., Burton, G., Lantos, C.P., Features of the shuttle pair 11β-hydroxyprogesterone/11-ketoprogesterone (1997) Steroids, 62, pp. 358-364
• Galigniana, M.D., Vicent, G.P., Piwien-Pilipuk, G., Burton, G., Lantos, C.P., Mechanism of action of the potent sodium-retaining steroid 11,19-oxidoprogesterone (2000) Mol. Pharmacol., 58, pp. 58-70
• Grassy, G., Fagart, J., Calas, B., Adenot, M., Rafestin-Oblin, M.E., Auzou, G., Structure-activity relationships of steroids with mineralocorticoid activity (1997) Eur. J. Med. Chem., 32, pp. 869-879
• Koshida, H., Miyamori, I., Soma, R., Matsubara, T., Ikeda, M., Takeda, R., Nakamura, S., Tsuda, Y., Mineralocorticoid and renal receptor binding activity of 21-deoxyaldosterone (1990) Endocrinology, 126, pp. 1410-1415
• Lantos, C.P., Burton, G., Roldán, A., Damasco, M.C., Aragonés, A., Structure-activity relationship in certain glucocorticoids and mineralocorticoids (1981) Physiopathology of Endocrine Diseases and Mechanisms of Hormone Action, pp. 477-494. , R.J. Soto, A. de Nicola, & J. Blaquier. New York: Alan R. Liss
• Lombès, M., Kenouch, S., Souque, A., Farman, N., Rafestin-Oblin, M.E., The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11β-hydroxysteroid dehydrogenase (1994) Endocrinology, 135, pp. 834-840
• Piwien-Pilipuk, G., Galigniana, M.D., Tautomycin inhibits phosphatase-dependent transformation of the rat kidney mineralocorticoid receptor (1998) Mol. Cell. Endocrinol., 144, pp. 119-130
• Piwien-Pilipuk, G., Kanelakis, K.C., Ghini, A.A., Lantos, C.P., Litwack, G., Burton, G., Galigniana, M.D., Modification of an essential amino group in the mineralocorticoid receptor evidences a differential conformational change of the receptor protein upon binding of antagonists, natural agonists and the synthetic agonist 11,19-oxidoprogesterone (2001) Biochim. Biophys. Acta, 1589, pp. 31-48
• Robertson, N.M., Schulman, G., Karnik, S., Alnemri, E., Litwack, G., Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using anti-MR antibody and confocal scanning microscopy (1993) Mol. Endocrinol., 7, pp. 1226-1239
• Sheppard, K.E., Funder, J.W., Type I receptors in parotid, colon and pituitary are aldosterone-selective in vivo (1987) Am. J. Physiol., 253, pp. E467-E471
• Souque, A., Fagart, J., Coutte, B., Davioud, E., Marquet, A., Rafestin-Oblin, M.E., The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent (1995) Endocrinology, 136, pp. 5651-5658
• Struhl, K., Histone acetylation and transcriptional regulatory mechanisms (1998) Genes Dev., 12, pp. 599-606
• Teutsch, G., Nique, F., Lemoine, G., Bouchoux, F., Cérède, E., Gofflo, D., Philibert, D., General structure-activity correlations of antihormones (1995) Ann. N.Y. Acad. Sci., 761, pp. 5-28
• Veleiro, A.S., Nevado, M.V., Monteserín, M.C., Burton, G., Syntheses of 21-hydroxy-11,19-oxidopregn-4-ene-3,20-dione and 21-hydroxy-6,19-oxidopregn-4-ene-3,20-dione (1995) Steroids, 60, pp. 358-364
• Young, D.B., Quantitative analysis of aldosterone's role in potassium regulation (1988) Am. J. Physiol., 255, pp. F811-F822

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------